|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Ranbaxy_Laboratories
U. S. rights to certain products
|
|
gptkbp:awards
|
Best Workplace
Innovation in Healthcare
Corporate Social Responsibility Award
|
|
gptkbp:ceo
|
Seigo Izumi
|
|
gptkbp:clinical_trial
|
Completed
Ongoing
Phase 1
Phase 2
Phase 3
|
|
gptkbp:community_engagement
|
Research funding
Volunteer programs
Health education programs
Charity partnerships
|
|
gptkbp:financials
|
Publicly traded
Revenue in billions
Profit margin
|
|
gptkbp:focus_area
|
gptkb:Research_and_Development
|
|
gptkbp:founded
|
gptkb:2005
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo Healthcare
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:market_position
|
gptkb:Europe
gptkb:Asia
gptkb:North_America
|
|
gptkbp:number_of_employees
|
Over 10,000
|
|
gptkbp:operates_in
|
Global
|
|
gptkbp:parent_company
|
gptkb:Daiichi_Sankyo_Company,_Limited
|
|
gptkbp:partnership
|
gptkb:Astra_Zeneca
gptkb:Boehringer_Ingelheim
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer
|
|
gptkbp:products
|
Vaccines
Biologics
Oncology drugs
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
gptkb:EMA
PMDA
|
|
gptkbp:research_focus
|
gptkb:Cardiovascular_diseases
Infectious diseases
Metabolic diseases
Central nervous system disorders
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:sustainability_initiatives
|
gptkb:administration
Social responsibility
Environmental responsibility
|
|
gptkbp:website
|
www.daiichisankyo.com
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo_Company,_Limited
|
|
gptkbp:bfsLayer
|
7
|